Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — FLORetina ICOOR 12th International Congress on OCT and OCT Angiography 2024
9 slides from Eyepoint's conference presentation, Dec 8, 2024
Slide 1: EYP-1901 versus Aflibercept for Previously-treated Wet AMD: DAVIO 2 Phase 2 1-Year Results
EYP-1901 (vorolanib intravitreal insert) versus Aflibercept for Previously-treated Wet Age-Related Macular Degeneration: DAVIO 2 Phase 2 1-Year Results Anat Loewenstein1 on behalf of DAVIO 2 investigators Stephanie Ruggiero,2 Monica Roy,2 Ramiro Ribeiro2 1. Tel Aviv Medical Center, Tel Aviv, Israel.
Slide 2: Disclosures
Presenter Disclosures Consultant: 4DMT, Abbvie, Alkeus, Annexon, Astellas, Apellis, Bayer Health Care, Beyeonics, EyePoint, J & J, NotalVision, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Ocuterra, Opthea, Oxurion, Roche, Syneos. Study Disclosures Disclosures These data are preliminary. Conclusi
Slide 3: EYP-1901 (DURAVYU): Vorolanib Intravitreal Insert
EYP-1901 (DURAVYUTM): Vorolanib Intravitreal Insert EYP-1901 Vorolanib Intravitreal Insert Controlled release over a Potent receptor tyrosine kinase Bioerodible, sustained period of at least 6 months inhibitor (TKI): selectively inhibits all IVT drug delivery VEGF signaling No delay – reaches target
Slide 4: DAVIO 2: Phase 2 Trial of EYP-1901 vs Aflibercept in Previously-treated Wet AMD
DAVIO 2: Phase 2 Trial of EYP-1901 vs Aflibercept in Previously-treated Wet AMD Baseline Primary endpoint characteristics EYP-1901 dosing Blend W28 & W32 ~2 years since diagnosis 161 patients W36 to mean; range, 0.1–20 years D1 W4 W8 W12 W16 W20 W24 W28 W32 W56 EYP-1901 2 mg low dose ~10 anti-VEGF i
Slide 5: Nearly Identical BCVA Change with EYP-1901 and Aflibercept at 12 Months
Nearly Identical BCVA Change with EYP-1901 and Aflibercept at 12 Months EYP-1901 dosing Extended durability & 15 Expected minimum duration of EYP-1901 in humans safety follow-up 10 BCVA change from baseline, ETDRS letters BCVA change from baseline, mean ± SD ETDRS letters Month 7/8 5 average Month 1
Slide 6: Demonstrated Strong Anatomic Control
EYP-1901 Demonstrated Strong Anatomic Control EYP-1901 dosing Extended durability & 100 Expected minimum duration of EYP-1901 in humans safety follow-up 50 CST change from baseline, μm CST change from baseline, Month 8 Month 12 EYP-1901 2 mg 17.8 21.2 mean ± SD μm EYP-1901 3 mg 10.6 11.1 0 Afliberce
Slide 7: 63% of EYP-1901 Treated Eyes Supplement-free up to Month 6
63% of EYP-1901 Treated Eyes Supplement-free up to Month 8 Proportion of eyes without supplemental aflibercept injections EYP-1901 dosing Extended durability & Expected minimum duration of EYP-1901 in humans safety follow-up 100% Eyes supplemental injection–free 80% up to specified week, %a 63% EYP-
Slide 8: EYP-1901 Demonstrated a Favorable Safety Profile in DAVIO 2
EYP-1901 Demonstrated a Favorable Safety Profile in DAVIO 2 Key Safety Findings • No EYP-1901–related ocular SAEs or systemic SAEs • No insert migration into the anterior chamber • No cases of retinal occlusive vasculitis • No discontinuations related to EYP-1901 treatment • ≈97% of AEs reported wer
Slide 9: Summary: DAVIO 2 Met Its Primary Endpoint
Summary: DAVIO 2 Met Its Primary Endpoint DAVIO 2 is the largest IVT TKI trial to date With one injection of EYP-1901: • EYP-1901 maintained stable visual acuity with strong anatomical control • 63% of EYP-1901-treated eyes were supplement-free up to 6 months after dosing EYP-1901 demonstrated • EYP